¼¼°èÀÇ ¸Á»ó½Å°æ¼¶À¯Á¾ Ä¡·á ½ÃÀå º¸°í¼­(2025³â)
Plexiform Neurofibroma Treatment Global Market Report 2025
»óǰÄÚµå : 1769713
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,263,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,052,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,842,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸Á»ó½Å°æ¼¶À¯Á¾ Ä¡·á ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ÀÇ·áºñ Áõ°¡, Èñ±ÍÁúȯ Ä¡·á¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø °­È­, ÀÎÁö¸¦ ³ÐÈ÷´Â ȯÀÚ Áö¿ø ´ÜüÀÇ °ü¿©ÀÇ È®´ë, ºñħ½ÀÀû Ä¡·á¹ý¿¡ ´ëÇÑ °ü½É Áõ°¡, ¿Ü°úÀû Á¢±Ùº¸´Ù °æ±¸¾à¿¡ÀÇ °æ»ç Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ÁÖ¸ñÇÒ ¸¸ÇÑ °æÇâÀ¸·Î´Â Ç¥Àû Ä¡·á¸¦ Áö¿øÇÏ´Â ºÐÀÚ »ý¹°ÇÐÀÇ È¹±âÀûÀÎ ¹ßÀü, Á¶±â Áø´ÜÀ» À§ÇÑ Á¤±³ÇÑ ¿µ»ó µµ±¸ÀÇ »ç¿ë È®´ë, ƯÁ¤ ½ÅÈ£ °æ·Î¸¦ ¸ñÇ¥·Î ÇÏ´Â »õ·Î¿î ¼ÒºÐÀÚ ¾à¹° °³¹ß, Ç×ü ±â¹Ý ¼Ö·ç¼ÇÀ» ÃËÁøÇÏ´Â »ý¸í°øÇÐÀÇ ÁøÀü µîÀÌ ÀÖ½À´Ï´Ù.

°³ÀÎÈ­µÈ ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¸Á»ó½Å°æ¼¶À¯Á¾ Ä¡·á ½ÃÀåÀÇ È®´ë¸¦ À̲ø °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ä¡·á È¿°ú¸¦ ³ô¿© °á°úÀÇ °³¼±°ú ºÎÀÛ¿ëÀÇ °æ°¨À» °¡Á®¿É´Ï´Ù. ¸ÂÃãÇü ÀÇ·áÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö´Â °¡¿îµ¥, ¸Á»ó½Å°æ¼¶À¯Á¾¿¡ ´ëÇÑ Å×ÀÏ·¯ ¸ÞÀ̵åÀÇ Ä¡·á Àü·«ÀÇ °³¹ßÀ» Áö¿øÇØ, °¢ ȯÀÚ¿¡ ƯÀ¯ÀÇ À¯ÀüÀÚ º¯À̳ª Á¾¾çÀÇ °Åµ¿¿¡ ´ëÀÀÇÕ´Ï´Ù. ¿¹¸¦ µé¸é, 2024³â 2¿ù, Personalized Medicine CoalitionÀº 2022³â¿¡ 12°³ÀÇ »õ·Î¿î °³º°È­ ÀǾàǰÀÌ ½ÂÀεǾúÀ¸¸ç, »õ·Î ½ÂÀÎµÈ Ä¡·á¹ý ÀüüÀÇ ¾à 34%¸¦ Â÷ÁöÇßÀ¸¸ç, ÀÌÀüº¸´Ù Å©°Ô Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ¸Á»ó½Å°æ¼¶À¯Á¾ Ä¡·á ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¸Á»ó½Å°æ¼¶À¯Á¾ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Ä¡·á ¼ºÀûÀ» Çâ»ó½Ã۱â À§ÇØ ÀúºÐÀÚ ¾ïÁ¦Á¦ µîÀÇ ¼±Áø Ä¡·áÀÇ °³¹ßÀ» Áß½ÃÇϰí ÀÖ½À´Ï´Ù. SpringWorks Therapeutics´Â °æ±¸ ÀúºÐÀÚ MEK ¾ïÁ¦Á¦ÀÎ GomekliÀÇ FDA ½ÂÀÎÀ» ¹ßÇ¥Çß½À´Ï´Ù. ±× °á°ú, ¼ºÀÎÀÇ 41%, ¼Ò¾ÆÀÇ 52% ȯÀÚ¿¡¼­ Á¾¾çÀÇ Ãà¼Ò°¡ È®ÀεǾú°í, Æò±Õ Á¾¾ç üÀûÀº ¼ºÀο¡¼­ 41%, ¼Ò¾Æ¿¡¼­ 42% °¨¼ÒÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Plexiform neurofibroma treatment encompasses medical strategies designed to manage and control the growth of complex nerve sheath tumors. The primary aim is to alleviate symptoms, avoid complications, and enhance the quality of life by addressing the tumor's effects on adjacent tissues and structures.

Key treatment options for plexiform neurofibroma include surgery, radiation therapy, chemotherapy, and targeted therapy. Surgery is a medical discipline that involves treating injuries, illnesses, or other conditions using manual and instrumental techniques, typically by performing incisions to remove, repair, or examine internal tissues or organs. It is utilized for various purposes such as alleviating pain, reducing tumor size, and restoring function in both children and adults. These procedures are carried out across diverse settings, including hospitals, clinics, and home care environments.

The plexiform neurofibroma treatment market research report is one of a series of new publications from The Business Research Company that provides plexiform neurofibroma treatment market statistics, including global market size, regional distributions, key competitors by market share, in-depth market segmentation, emerging trends, opportunities, and all other essential insights to succeed in the plexiform neurofibroma treatment industry. This market research report offers a comprehensive overview and detailed evaluation of the current and projected industry landscape.

The plexiform neurofibroma treatment market size has grown strongly in recent years. It will grow from $1.33 billion in 2024 to $1.45 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. This historical growth was driven by a rising incidence of neurofibromatosis type 1, enhanced global awareness and diagnostic efforts for plexiform neurofibroma, increased R&D funding from pharmaceutical firms, an expanding portfolio of promising drug candidates in clinical stages, and improvements in healthcare infrastructure.

The plexiform neurofibroma treatment market size is expected to see strong growth in the next few years. It will grow to $1.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. Factors contributing to this projected growth include rising health expenditures, stronger government support for rare disease therapies, greater involvement of patient advocacy groups spreading awareness, increasing interest in non-invasive treatment methods, and a growing inclination toward oral medications over surgical approaches. Notable trends during the forecast period include breakthroughs in molecular biology supporting targeted treatments, greater use of sophisticated imaging tools for early diagnosis, development of new small-molecule drugs aimed at specific signaling pathways, progress in biotechnology promoting antibody-based solutions, and advancements in biomarker discovery for tracking disease evolution.

The growing demand for personalized medicine is anticipated to drive the expansion of the plexiform neurofibroma treatment market. Personalized medicine is a healthcare approach that tailors medical treatment based on an individual's genetic profile, biological characteristics, and personal health data. This approach enhances treatment effectiveness by aligning therapies with a patient's specific genetic and biological profile, resulting in improved outcomes and reduced side effects. As the need for personalized medicine increases, it supports the development of tailored therapeutic strategies for plexiform neurofibroma, addressing unique genetic mutations and tumor behaviors in each patient. For example, in February 2024, the Personalized Medicine Coalition, a US-based professional membership organization, reported that 12 new personalized medicines received approval in 2022, accounting for approximately 34% of all newly approved therapies, marking a significant rise from previous years. Consequently, the rising demand for personalized medicine is fueling growth in the plexiform neurofibroma treatment market.

Leading companies in the plexiform neurofibroma treatment market are emphasizing the development of advanced treatments, such as small-molecule inhibitors, to improve therapeutic outcomes. Small-molecule inhibitors are low-molecular-weight compounds designed to interfere with specific proteins or enzymes to disrupt abnormal cellular activities. For instance, in February 2025, SpringWorks Therapeutics, a US-based biopharmaceutical firm, announced FDA approval for Gomekli, an oral small-molecule MEK inhibitor. Gomekli is approved for use in adults and children aged two years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas that are not surgically resectable. Clinical trials revealed that 41% of adults and 52% of pediatric patients experienced confirmed tumor size reduction, with average tumor volume decreasing by 41% in adults and 42% in children. Furthermore, responses lasting at least 12 months were observed in 88% of adults and 90% of children, with nearly half of all patients in both groups maintaining their response for over 24 months.

In April 2025, Merck Group, a Germany-based pharmaceutical company, acquired SpringWorks Therapeutics for $3.4 billion. The acquisition is aimed at immediately boosting Merck's healthcare revenues, accelerating its mid- to long-term growth, and enhancing its presence in the U.S. market. This strategic move broadens Merck's portfolio in rare tumors and rare diseases, as SpringWorks contributes two FDA-approved treatments-Ogsiveo for desmoid tumors and Gomekli for neurofibromatosis type 1-associated plexiform neurofibromas. SpringWorks Therapeutics is a U.S.-based biopharmaceutical company specializing in treatments for plexiform neurofibroma.

Major players in the plexiform neurofibroma treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceuticals Industries Limited, Aurobindo Pharma, Amneal Pharmaceuticals LLC, Endo Pharmaceuticals Inc., Exelixis Inc., Mallinckrodt Plc, SpringWorks Therapeutics, Sangamo Therapeutics Inc., Recursion Pharmaceuticals Inc., Noveome Biotherapeutics Inc., and BioXcel Therapeutics Inc.

North America was the largest region in the plexiform neurofibroma treatment market in 2024. The regions covered in plexiform neurofibroma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the plexiform neurofibroma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The plexiform neurofibroma treatment market consists of revenues earned by entities by providing services such as genetic testing, clinical evaluation, multidisciplinary care coordination, and clinical trial management. The market value includes the value of related goods sold by the service provider or included within the service offering. The plexiform neurofibroma treatment market also includes sales of tumor monitoring kits, genetic testing kits, clinical decision support tools, and rehabilitation aids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Plexiform Neurofibroma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on plexiform neurofibroma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for plexiform neurofibroma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The plexiform neurofibroma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Plexiform Neurofibroma Treatment Market Characteristics

3. Plexiform Neurofibroma Treatment Market Trends And Strategies

4. Plexiform Neurofibroma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Plexiform Neurofibroma Treatment Growth Analysis And Strategic Analysis Framework

6. Plexiform Neurofibroma Treatment Market Segmentation

7. Plexiform Neurofibroma Treatment Market Regional And Country Analysis

8. Asia-Pacific Plexiform Neurofibroma Treatment Market

9. China Plexiform Neurofibroma Treatment Market

10. India Plexiform Neurofibroma Treatment Market

11. Japan Plexiform Neurofibroma Treatment Market

12. Australia Plexiform Neurofibroma Treatment Market

13. Indonesia Plexiform Neurofibroma Treatment Market

14. South Korea Plexiform Neurofibroma Treatment Market

15. Western Europe Plexiform Neurofibroma Treatment Market

16. UK Plexiform Neurofibroma Treatment Market

17. Germany Plexiform Neurofibroma Treatment Market

18. France Plexiform Neurofibroma Treatment Market

19. Italy Plexiform Neurofibroma Treatment Market

20. Spain Plexiform Neurofibroma Treatment Market

21. Eastern Europe Plexiform Neurofibroma Treatment Market

22. Russia Plexiform Neurofibroma Treatment Market

23. North America Plexiform Neurofibroma Treatment Market

24. USA Plexiform Neurofibroma Treatment Market

25. Canada Plexiform Neurofibroma Treatment Market

26. South America Plexiform Neurofibroma Treatment Market

27. Brazil Plexiform Neurofibroma Treatment Market

28. Middle East Plexiform Neurofibroma Treatment Market

29. Africa Plexiform Neurofibroma Treatment Market

30. Plexiform Neurofibroma Treatment Market Competitive Landscape And Company Profiles

31. Plexiform Neurofibroma Treatment Market Other Major And Innovative Companies

32. Global Plexiform Neurofibroma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Plexiform Neurofibroma Treatment Market

34. Recent Developments In The Plexiform Neurofibroma Treatment Market

35. Plexiform Neurofibroma Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â